<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03467529</url>
  </required_header>
  <id_info>
    <org_study_id>RC16_0456</org_study_id>
    <nct_id>NCT03467529</nct_id>
  </id_info>
  <brief_title>Evaluation of Full-field Coherence Tomography for ex Vivo Staging and Assessment of Superficial Esophageal Squamous Carcinoma: a Pilot Study</brief_title>
  <acronym>OESOCiTy</acronym>
  <official_title>Evaluation of Full-field Coherence Tomography for ex Vivo Staging and Assessment of Superficial Esophageal Squamous Carcinoma: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      New tools are needed to 1) diagnose and 2) stage early esophageal squamous cell carcinoma&#xD;
      (SCC) in order to improve outcomes of this frequent and lethal cancer.&#xD;
&#xD;
      Optical coherence tomography (OCT) is an optical technique, which can image human tissue ex&#xD;
      vivo and in vivo with a resolution around 30µm and with a depth of 1mm. Full-field optical&#xD;
      coherence tomography (FFOCT) is a new modality, which allows to image an ex vivo specimen&#xD;
      with a cellular resolution and to perform 3D reconstruction. This device has never been&#xD;
      tested on esophageal specimens.&#xD;
&#xD;
      Therefore, the aim of this non-interventional research is 1) to determine FFOCT diagnostic&#xD;
      criteria for SCC and 2) to figure if FFOCT allows the staging of the depth of invasion in&#xD;
      SCC.&#xD;
&#xD;
      To achieve these goals, we will image ex vivo 10 specimens of endoscopic resection of SCC&#xD;
      (endoscopic mucosal resection (EMR) and submucosal dissection (ESD)) using an FFOCT device&#xD;
      and we will compare the results with histological analysis of these specimens.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      General study methodology&#xD;
&#xD;
      The study presents the following characteristics:&#xD;
&#xD;
        -  Observational&#xD;
&#xD;
        -  Non interventional imaging study&#xD;
&#xD;
        -  Single-centre&#xD;
&#xD;
        -  Not controlled&#xD;
&#xD;
        -  Prospective Tests and analysis CRF&#xD;
&#xD;
        -  Filled by the investigator&#xD;
&#xD;
        -  Data from the medical file of the patient Imaging&#xD;
&#xD;
        -  As standard of care&#xD;
&#xD;
        -  Before endoscopic resection the lesion will be characterized and pictures will be made&#xD;
           using white light endoscopy, magnification techniques and electronic chromoendoscopy&#xD;
&#xD;
        -  Immediately after endoscopic resection, the specimen will be prepared, oriented and&#xD;
           scanned using the FFOCT device (CE marking)&#xD;
&#xD;
        -  Imaging movies will be then reviewed by trained readers and compared to movies of&#xD;
           healthy patients, findings will be described&#xD;
&#xD;
        -  Imaging movies will be compared to pathology slides&#xD;
&#xD;
      Pathology&#xD;
&#xD;
        -  After scanning the specimen will be sent to pathology for analysis&#xD;
&#xD;
        -  The pathology slides will be scanned to be kept in the study record together with their&#xD;
           interpretation&#xD;
&#xD;
      Study schedule&#xD;
&#xD;
        -  Total length of study: 24 months&#xD;
&#xD;
        -  Methodology and regulatory: 6 months&#xD;
&#xD;
        -  Recruitment period: 1 year&#xD;
&#xD;
        -  Recruitment among the patients scheduled for the endoscopic procedure in the operative&#xD;
           room&#xD;
&#xD;
        -  One single visit = inclusion the day of the procedure&#xD;
&#xD;
        -  No follow-up required&#xD;
&#xD;
        -  Analyses: 3 months&#xD;
&#xD;
        -  Paper writing: 3 months&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 6, 2018</start_date>
  <completion_date type="Anticipated">October 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Concordance between FFOCT findings and pathology based on the Paris classification of superficial esophageal cancer in pathology</measure>
    <time_frame>Immediately after endoscopic resection (Day 0)</time_frame>
    <description>The principal objective of this study will be reached if:&#xD;
the tumoral lesion is correctly identified in the specimen in FFOCT images&#xD;
and/or the normal esophageal mucosa and submucosal and/or normal vessels are correctly identified in the specimen in FFOCT images&#xD;
in at least 8 specimens.</description>
  </primary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Esophagus Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non interventional study</intervention_name>
    <description>Non interventional study</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        10 patients will be recruited by the Clinical investigation center by reviewing the&#xD;
        scheduled SCC resections each week. All patients scheduled for an endoscopic resection of&#xD;
        SCC will be considered for inclusion in the study. The study itself will take place in the&#xD;
        department of gastroenterology. Recruitment within one year of inclusion will be possible&#xD;
        because our unit is a regional reference center for interventional endoscopy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age of 18 years and more&#xD;
&#xD;
          -  Confirmed diagnosis of SCC based on previous biopsy&#xD;
&#xD;
          -  Indication for endoscopic resection&#xD;
&#xD;
          -  Patient who has read the information notice and confirmed its willing to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Any contraindication for endoscopic treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lucille Quénéhervé, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lucille Quénéhervé, Dr</last_name>
    <phone>+33 (0)2-40-08-31-52</phone>
    <email>lucille.queneherve@chu-nantes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emmanuel Coron, Pr</last_name>
    <phone>+33 (0)2-40-08-30-97</phone>
    <email>emmanuel.coron@chu-nantes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>QUENEHERVE Lucille, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 4, 2017</study_first_submitted>
  <study_first_submitted_qc>March 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2018</study_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Superficial esophageal cancer</keyword>
  <keyword>Squamous cell cancer</keyword>
  <keyword>Mini invasive imaging</keyword>
  <keyword>Pre therapeutic assessment</keyword>
  <keyword>Optical coherence tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

